Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
SOLO COVID-19 is the evidence Oncodesign’s pharmacological expertise combined with our agility and societal commitment.
This new offering was rapidly spread out in 2020, to allow – with rigor and safety – the performance of specific in vitro and in vivo pharmacology studies to assess new preventive, therapeutic or vaccine approaches to the treatment of COVID-19.
In collaboration with our partners IDMIT and SEPIA from CEA, SOLO PoC Covid-19 offers an integrated panel of in vitro assays and animal models infected with Sars-CoV-2.
Biochemical assays for Spike S protein binding, Sars-CoV-2 viral protease activities, human ACE2 protein binding and human TMPRSS2 protease activity.
Infection tests of human and simian cells by the original Sars-CoV-2 variant and its variants (English, South African, Brazilian and Indian) to assess the potential of compounds on viral load, cytopathogenic effect, immune modulation and air-liquid interface.
Models of Sars-CoV-2 infection of transgenic mice, or non-lethal native infection of hamsters and non-human primates, to assess the preventive protective activity of new vaccines or the pharmacological efficacy of new therapeutic agents or repositioned compounds, integrating multiple analyses including imaging.
Severe inflammatory model of pulmonary fibrosis in mice, to assess the proof of concept of therapeutic solutions oriented in the management and treatment of post-acute respiratory distress syndrome.